Anti‐factor Xa activity of enoxaparin administered at prophylactic dosage to patients over 75 years old
Population
189 consecutive patients aged >75 years receiving venous thromboembolism prophylaxis
Design
Cohort
Follow-up
throughout treatment
Authors
Discussion
Loading...
Member takes
Implication
Monitoring anti-Xa activity may not identify major bleeding risk with prophylactic enoxaparin in the elderly; hypothesis-generating and requires prospective validation.
Structured PICO
P
Population
189 consecutive patients aged >75 years (mean age 82 ± 5 years, 22% weighing <50 kg, 50% presenting renal impairment according to the Cockcroft and Gault formula) receiving venous thromboembolism prophylaxis
I
Intervention
Enoxaparin 4000 IU once daily
O
Outcome
Distribution parameters of anti-Xa activitysurrogate
Systematic monitoring of anti-Xa activity in elderly patients treated with prophylactic enoxaparin does not appear necessary to prevent major bleeding.
Cite This Study
Berges et al. (2007) studied this question.